Summary
Pfizer Inc.'s 2007 Form 10-K reveals a pharmaceutical giant navigating the dual challenges of patent expirations and the introduction of new blockbuster drugs. While facing revenue declines due to the loss of exclusivity for key products like Norvasc and Zoloft, the company's Pharmaceutical segment remains the dominant revenue driver, contributing over 91% of total revenues. Significant R&D investment of $8.1 billion underscores Pfizer's commitment to future growth through innovation, with a robust pipeline of 213 projects in development. The Animal Health segment showed strong growth, increasing revenues by 14%. Investors should note the ongoing patent challenges for major products like Lipitor and Celebrex, which represent a significant risk factor. The company is actively pursuing acquisitions and licensing to bolster its product portfolio. Despite the pressures from generic competition and managed care organizations, Pfizer's global presence, with over 52% of revenues generated internationally, provides diversification. The company's ability to manage patent cliffs, successfully launch new therapies, and adapt to evolving regulatory and pricing environments will be crucial for its future financial performance.
Financial Highlights
28 data points| Revenue | $48.42B |
| Cost of Revenue | $11.24B |
| Gross Profit | $37.18B |
| SG&A Expenses | $15.63B |
| Net Income | $8.14B |
| EPS (Basic) | $1.18 |
| EPS (Diluted) | $1.17 |
| Shares Outstanding (Basic) | 6.92B |
| Shares Outstanding (Diluted) | 6.94B |
Key Highlights
- 1Pharmaceutical segment remains the largest contributor to revenue (91.8% in 2007), though it experienced a 1% decline due to patent expirations of Norvasc and Zoloft.
- 2Significant investment in Research and Development ($8.1 billion in 2007) to drive future growth, with 213 projects in development.
- 3Animal Health segment demonstrated strong growth, with revenues increasing by 14% to $2.6 billion.
- 4Key products like Lipitor, Norvasc, and Celebrex generated significant revenue (over $2 billion each in 2007), but major products face patent expiration challenges or legal challenges to patents.
- 5Over 52% of total revenues were generated from international operations, highlighting global diversification.
- 6The company completed the sale of its Consumer Healthcare business in December 2006 for $16.6 billion.
- 7Substantial share repurchase program in place, with over 104 million shares repurchased in Q4 2007.